Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide

Leuk Res. 2010 Jul;34(7), Constantin A. Dasanu, Michael A. Reale, Frank Bauer

Cyclin D1 is a chief regulator of the cell cycle and transcriptional processes [1]. Among other human cancers, it is expressed in mantle cell lymphoma (MCL), where its encoding gene CCND1 is activated by the t(11;14)(q13;q32) in almost 100% of cases. Through an alternative splicing, CCND1 generates two mRNAs, cyclin D1a and D1b, which differ in their C-terminus. It is currently thought that cyclin D1b could represent a nuclear oncogene. In clinical practice, identification of cyclin D1 over-expression...

NOT A MEMBER?

Registration is FREE

  • Up-to-date oncology news
  • Journal article summaries
  • Commentaries and interviews
  • Drug and interactions database
  • Chemotherapy regimens
  • Daily e-newsletters

 

Editors' Choice

Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)

Sign up for our newsletters

Too busy to follow cancer's top stories? Sign-up for 1 or more of our free newsletters -- delivered weekly to your inbox.

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
  • Forgot your password?
    Not a member? Free registration